# OnCo record ambrx (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ambrx/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ambrx" ;
  schema:name "Ambrx"@en ;
  schema:alternateName "Ambrx, Inc."@en, "Ambrx Inc"@en, "Ambrx Biopharma"@en ;
  schema:description "Ambrx is a La Jolla, California biotechnology company founded in 2003 whose HER2 antibody-drug conjugate ARX788 is in OnCo's phase 3 ACE-Breast-02 trial (with Zhejiang Medicine, in China) and the global phase 2 ACE-Breast-03 trial after trastuzumab deruxtecan."@en ;
  schema:url <https://onco.cc/companies/ambrx/>, <http://ambrx.com/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <http://ambrx.com/>, <https://www.wikidata.org/wiki/Q100955904>, <https://clinicaltrials.gov/search?lead=Ambrx%2C%20Inc.> ;
  onco:tag "ctgov-sponsor", "wave5-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/arx788/> ;
  onco:trials <https://onco.cc/trials/ace-breast-02/>, <https://onco.cc/trials/nct04829604/> .